Download PDF
Thorac Cardiovasc Surg
DOI: 10.1055/a-2514-2076
Reply to Letter to the Editor

“Standardization of Myocardial Protection: Comment on Cardiac Surgery 2023 Reviewed”

Murat Mukharyamov
1   Department of Cardiothoracic Surgery, Jena University Hospital, Friedrich Schiller University of Jena, Jena, Germany
,
Hristo Kirov
1   Department of Cardiothoracic Surgery, Jena University Hospital, Friedrich Schiller University of Jena, Jena, Germany
,
Tulio Caldonazo
1   Department of Cardiothoracic Surgery, Jena University Hospital, Friedrich Schiller University of Jena, Jena, Germany
,
Torsten Doenst
1   Department of Cardiothoracic Surgery, Jena University Hospital, Friedrich Schiller University of Jena, Jena, Germany
› Author Affiliations
› Further Information
    Permissions and Reprints All articles of this category

Standardization of Myocardial Protection: Comment on Cardiac Surgery 2023 Reviewed

We thank the authors for their comments on our recent cardiac surgery reviewed article. They refer to the myocardial protection section in the article which, for space reasons consisted of one small paragraph, which was kept general and cannot address specific aspects. However, we had mentioned in a subclause that current cardioplegia solutions are at least 30 years old. The authors here present their recent work on a new cardioplegic solution that has just received Conformité Européenne certification.[1] We reviewed the field of myocardial protection in a different article earlier, in which we dove into details of mechanisms and outcomes and also illustrated the potential for future developments.[2] At that time we were only aware of the newly approved Custodiol N[3] [4] solution and most of the authors' experiences seem to be published just recently.[5] It is therefore enlightening to realize that cardioplexol has also received approval as a new cardioplegic solution. It will now depend on the market penetration of these two new solutions, whether we will have to revise our statement from above.



Publication History

Received: 13 November 2024

Accepted: 29 November 2024

Article published online:
28 January 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Letter to this article:

Standardization of Myocardial Protection: Comment on Cardiac Surgery 2023 ReviewedThorac Cardiovasc Surg eFirst
DOI: 10.1055/a-2496-5428

 

  • References

  • 1 Tevaeara Stahel H, Barandun S, Kaufmann E. et al. Single-center experience with the combination of Cardioplexol™ cardioplegia and MiECC for isolated coronary artery bypass graft procedures. J Thorac Dis 2019; 11 (Suppl. 10) S1471-S1479
    CrossrefPubMedSearch in Google Scholar
  • 2 Mukharyamov M, Schneider U, Kirov H, Caldonazo T, Doenst T. Myocardial protection in cardiac surgery-hindsight from the 2020s. Eur J Cardiothorac Surg 2023; 64 (06) ezad424
    CrossrefPubMedSearch in Google Scholar
  • 3 Veres G, Radovits T, Merkely B, Karck M, Szabó G. Custodiol-N, the novel cardioplegic solution reduces ischemia/reperfusion injury after cardiopulmonary bypass. J Cardiothorac Surg 2015; 10: 27
    CrossrefPubMedSearch in Google Scholar
  • 4 Szabó G, Brlecic P, Loganathan S. et al. Custodiol-N versus Custodiol: a prospective randomized double-blind multicentre phase III trial in patients undergoing elective coronary bypass surgery. Eur J Cardiothorac Surg 2022; 62 (05) ezac287
    CrossrefPubMedSearch in Google Scholar
  • 5 Tevaearai HT, WG, Landowski P, Carrel T, Schmidli J, Voet B, Grabenwöger M. A single-centre, single-blind, randomized, active-controlled phase 3 non-inferiority study to investigate the safety and efficacy of the cardioplegic solution Cardioplexol™. Front Cardiovasc Med 2024 ;2024 (Submitted)
    PubMedSearch in Google Scholar